A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Intravenously and Subcutaneously Administered REGN2477 in Healthy Women Not of Childbearing Potential

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Intravenously and Subcutaneously Administered REGN2477 in Healthy Women Not of Childbearing Potential

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs REGN 2477 (Primary)
  • Indications Fibrodysplasia ossificans progressiva
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 16 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 10 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 19 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top